Quantitative investigation of terbinafine hydrochloride absorption into a living skin equivalent model by MALDI-MSI by Russo, Cristina et al.
Quantitative investigation of terbinafine hydrochloride 
absorption into a living skin equivalent model by MALDI-
MSI
RUSSO, Cristina, BRICKELBANK, Neil, DUCKETT, Catherine 
<http://orcid.org/0000-0002-6845-1890>, MELLOR, Steve, RUMBELOW, 
Stephen and CLENCH, Malcolm <http://orcid.org/0000-0002-0798-831X>
Available from Sheffield Hallam University Research Archive (SHURA) at:
http://shura.shu.ac.uk/22212/
This document is the author deposited version.  You are advised to consult the 
publisher's version if you wish to cite from it.
Published version
RUSSO, Cristina, BRICKELBANK, Neil, DUCKETT, Catherine, MELLOR, Steve, 
RUMBELOW, Stephen and CLENCH, Malcolm (2018). Quantitative investigation of 
terbinafine hydrochloride absorption into a living skin equivalent model by MALDI-
MSI. Analytical chemistry, 90 (16), 10031-10038. 
Copyright and re-use policy
See http://shura.shu.ac.uk/information.html
Sheffield Hallam University Research Archive
http://shura.shu.ac.uk
 1 
 
Quantitative investigation of Terbinafine Hydrochloride Absorption into 
a Living Skin Equivalent Model by MALDI-MSI 
 
Cristina Russo1, Neil Brickelbank1, Catherine Duckett1, Steve Mellor2, Stephen Rumbelow3 and 
Malcolm R Clench1 
1Centre for Mass Spectrometry Imaging, Biomolecular Research Centre, Sheffield Hallam 
University, Howard Street, Sheffield S1 1WB, UK 
2Croda International Plc, Cowick Hall, Snaith, Goole, East Yorkshire DN14 9AA, UK 
3Croda Inc, Croda Inc 315 Cherry Lane New Castle Delaware 19720, USA 
 
 
 
Abstract 
The combination of microspotting of analytical and internal standards, matrix sublimation and 
recently developed software for quantitative mass spectrometry imaging has been used to develop 
a high resolution method for the determination of Terbinafine hydrochloride in the epidermal region 
of a full thickness living skin equivalent model. A quantitative assessment of the effect of the 
addition of the penetration enhancer (dimethyl isosorbide (DMI)) to the delivery vehicle has also 
been performed and data have been compared to those obtained from LC/MS/MS measurements 
of homogenates of isolated epidermal tissue. At 10% DMI the levels of signal detected for the drug 
in the epidermis were 0.20 ± 0.072 mg/g tissue for QMSI and 0.28 ± 0.040 mg/g tissue for 
LC/MS/MS; at 50% DMI 0.69 ± 0.23 mg/g tissue for QMSI and 0.66 ± 0.057 mg/g tissue for 
LC/MS/MS. Comparison of means and standard deviations indicates no significant difference 
between the values obtained by the two methods. 
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Introduction  
 
The skin is used  as route of drug administration both for compounds intended as topical 
treatments and for those intended as systemic treatments where there is a requirement to avoid 
the first pass effect.1 Since there are issues in reliably obtaining human skin for pre-clinical studies 
(and sufficient skin for a representative study given issues including, race, gender, age and genetic 
polymorphisms) there is a great deal of interest in the use of 3D in vitro  tissue engineered models 
of human skin as reproducible and easy to obtain testing platforms.1 In a recent review by Mathes 
et al.  the use of these models in drug development has been described.2 Skin models 
commercially available include: human reconstructed epidermis (HRE), 3D differentiated epidermis 
cultures derived from human keratinocytes, i.e. EpiSkin (Epskin, Lyon, France) and EpiDerm 
(Mattek, Ashland USA) and full thickness living skin equivalents (LSE) e.g. EpiDermFT (Mattek 
Ashland USA), T-skin (Episkin, Lyon, France) and Labskin (Innovenn(UK) Ltd York UK).3 
 
 
Mass spectrometry imaging (MSI) is a relatively new and powerful technique able to study intact 
tissue sections providing ion distribution maps of many non-labelled endogenous and exogenous 
species simultaneously. This is a distinct advantage in comparison to conventional techniques, 
such as immunohistochemistry and radiolabelling. The absence of the label makes this technique 
fast, relatively inexpensive. It has been used extensively in studies of pharmaceutical distribution4 
and its use to study skin absorption was one of the first applications of MSI in pharmaceutical 
analysis to be reported.5  
 
The application of mass spectrometry imaging (MSI) to 3D in vitro tissue models of human skin 
represents a valid approach for investigating either drug absorption or drug biotransformation in 
skin. Arvey et al.6 were the first to combine MSI with a comercially available 3D tissue model of the 
epidermis “Straticel” in order to analyse the penetration of the drug imipramine. In later work 
conducted by Francese et al.7 and Mitchell et al.8 full thickness living skin equivalents (LSEs) were 
used as models to be analysed by MALDI-MSI. Such models consist of a full differentiated 
epidermal layer supported by a dermal component generated by seeding fibroblasts into a 3D 
scaffold. The aim of the work reported by Francese et al.7 was to evaluate the efficiency of 
curcumin as a MALDI matrix. After the application of this matrix, MALDI-MSI was used to plot the 
localization of the drug acetretin within Labskin, a commercial living skin equivalent model. This 
study demonstrated that at 4 hours post treatment the drug had penetrated into the epidermal 
layer. In a more recent work, Harvey et al.9 used MALDI-MSI to map the same drug acetrin in 
Labskin models, in which psoriasis was induced by treating the samples with the proinflammatory 
cytokine interleukin-22. This study showed that at 24 hours post treatment the drug was localised 
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onto the epidermal layer, whereas after 48 hours the drug had penetrated into the dermal region.9 
Such studies have demonstrated that the widespread adoption of MSI in skin research could 
contribute to the study of drug/toxicant absorption, drug/toxicant response, infection, would-healing 
and burns.  
 
In MALDI-MSI the nature of analyte ionization depends strongly on the entity of the analyte as well 
as the tissue. The same molecule can be subjected to varying ion suppression effects in different 
tissues or across the same tissue in response to a changeable histological framework as well as to 
the ionization competition with compounds within the morphological microenviroment.10 This 
aspect in addition to the variation of ion signals due to heterogeneity of matrix deposition represent 
the major issues that need to be addressed in the development MALDI-MSI as a method for 
quantitative mass spectrometry imaging (QMSI). A recently published review conducted by 
Rzagalinski et al. investigated multiple approches and strategies for quantification of small 
molecules using MALDI-MSI in order to correct these limitations.11 Particular attention was focused 
on the strategy used to create calibration curves based on the use of serial dilution of standard. In 
order to mimic suppression ion effects within tissue, it has been common to either use mimetic 
arrays created from tissue homogenates12 or to spot working standard solutions using a control 
tissue in two different ways: 1) by spotting a range of standard concentration onto the tissue prior 
to depositing the matrix or 2) by spotting a range of concentration underneath of tissue prior to 
positioning the tissue and depositing the matrix. Lagarrigue et al. used spotting onto tissue in order 
to quantify the amount of pesticide chloredecon within mouse liver section.13 In this study six 
replicates were performed and a good linearity coefficient was achieved (R2 from 0.9807 to 
0.9981).  In contrast Pirman et al. spotted a range of calibration standard underneath a control 
brain tissue in order to quantify levels of cocaine by visualization of the expected major product ion 
at m/z 182 using MALDI-MS/MS imaging.14 
 
The effect of tissue composition on signal response in MSI has large implications when skin is the 
target organ for quantitative experiments. The layers of the skin comprise distinct cell types and 
hence each skin layer would be expected to give a slightly different response for the same amount 
of analyte. This implies that mimetic arrays created from skin homogenates would not be a suitable 
methodology for calibration in this instance. A recent paper by Chumbley et al.15 reported the use 
of an acoustic micro-spotter16 for the creation of calibration arrays in a study of the quantification of 
rifampicin in liver tissues. It was reported that the use of the acoustic spotter enabled picolitre 
volumes of standard solutions to be reproducibly and accurately spotted onto tissue sections. It 
was decided to investigate the use of acoustic microspotting of standards as a way of calibrating 
QMSI experiments where the object was to quantify the amount of a compound in a defined skin 
layer. 
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The object of this study is to obtain absolute quantitation of the amount of an antifungal agent, 
Terbinafine hydrochloride, in the epidermal layer of a 3D living skin equivalent model. Terbinafine 
is an antifungal belonging to allylamine class and it acts by blocking sqalene epoxidase. The 
hydrochloride form of Terbinafine has been included in topical formulations for the treatment of  
dermatophytoses,  pityriasis versicolor and cutaneous candidiasis.17 Since the aim of drug delivery 
systems for Terbinfine is topical delivery rather than transdermal delivery, in order to assess their 
efficiency, methodologies for the quantitation of Terbinafine in skin rather than measurements of 
permeation through skin e.g. Franz-Cell diffusion measurements18 are required. Of interest in such 
measurements is how the addition of penetration enhancers e.g. Dimethyl Isosorbide (DMI) to the 
delivery formulation affects the amount of drug at the target site (i.e. the epidermis).19 The model 
chosen for this study is Labskin, a full thickness skin model produced by seeding a fibrin scaffold 
with fibroblasts and keratinocytes. The model has been extensively used for mass spectrometry 
imaging experiments due to its good physical strength and ease of crysectioning. 
 
In the study reported here the combination of microspotting of analytical and internal standards, 
matrix sublimation and recently developed software for QMSI20 has been used to develop a high 
resolution QMSI method for the determination of Terbinafine hydrochloride in the epidermal region 
of living skin equivalent model and a quantitative assessment of the effect of the addition of the 
penetration enhancer DMI to the delivery vehicle. These data have been compared to data 
obtained from LC/MS/MS measurements of homogenates of isolated epidermal tissue. 
 
Experimental 
 
i. Materials 
Alpha cyano-4-hydroxycinnamic acid (α-CHCA), acetonitrile (ACN), phoshorus red, Terbinafine 
hydrochloride standard (TBF HCl, MW 327.89), isosorbide dimethyl ether (DMI), haematoxylin, 
eosin, xylene substitute, ethanol (EtOH) and formic acid ≥ 96% (FA) were purchased from Sigma-
Aldrich (Gillingham, UK). 
Pertex mounting medium was obtained from Leica Microsystems (Milton Keynes, UK). 
LC-grade methanol (MeOH) and LC-grade acetonitrile (ACN) were purchased from Fisher 
Scientific. 18 MΩ water was obtained from an ELGA water purification system (Buckinghamshire, 
UK). 
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The internal standard Terbinafine d7 hydrochloride (TBF-d7 HCl, MW 334.93) was obtained by 
Clearsynth (Maharashtra, India).  Gentian violet 1% was purchased from De La Cruz Laboratories 
Inc. (Califiornia, USA). 
 
Labskin living skin equivalent (LSE) samples were provided by Innovenn (UK) Ltd (York, England). 
 
 
 
 
ii. Sample treatment 
 
Living skin equivalent (LSE) samples were obtained at day 7 air liquid interface (ALI) and 
incubated in Labskin maintenance media for 24 hours within 5% CO2 at 37°C.  
For the experiment, three LSE samples were treated with 20 µL of Terbinafine hydrochloride (1% 
w/w) dissolved in an emulsion made up of water/olive oil (80:20 v/v) with either 10% or 50% DMI 
and incubated for 24 hours. For the vehicle control group, three LSEs samples were treated with 
20 µL of the emulsion water/olive oil (80:20 v/v) alone and incubated for 24 hours. 
After incubation, the samples were taken and washed with LC-grade MeOH to remove excess 
formulation and, then, snap-frozen with liquid nitrogen cooled isopentane (2-5 min) and stored at -
80°C.  
For cryosectioning, LSEs were transferred into the cryostat (Leica 200 UV, Leica Microsystems, 
Milton Keynes, UK), mounted onto cork ring using dH2O at -25°C for 30 min to allow to thermally 
equilibrate. 12 μm tissue sections were cryosectioned, thaw mounted onto polylysine glass slides 
and stored at -80°C.  
Before matrix application and imaging the samples were freeze-dried under vacuum (0.035 mBar) 
for 2 hours to avoid delocalization of the analyte and preserve the integrity of the tissues. 
 
iii. Preparation of Standard Curves 
 
For MALDI-MSI experiments, working standards were made to 0.01, 0.1, 1, 10, 100, 500, 1000 and 
1500 ng/µL of TBF HCl with 100 ng/µL of the internal standard TBF d7 HCl in MeOH/H2O (50:50). 
Calibration standards were applied onto the epidermis area of 12 µm thick sections of blank tissue 
sections using an acoustic robotic spotter (Portrait 630, Labcyte Inc., Sunnyvale, CA). 
9 microspots of internal standard TBF-d7 hydrochloride (100 ng/µL in MeOH/H2O (50:50)) were 
deposited onto the epidermis of a vehicle control Labskin section treated with water/olive oil 
(80:20) alone and two Labskin samples treated with Terbinafine hydrochloride 1% w/w in 
water/olive oil (80:20) with either 10% or 50% DMI. 
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For application of the standards and internal standard, the number of cycles for each spot was set 
to 20 for a total volume of 3.4 nL of each deposited solution. 5 extra spots were applied outside the 
tissue to give a “drying time” between each cycle. 
 
For LC-MSMS, calibration standards were made to 0.001, 0.01, 0.05, 0.1, 0.5, 1, 10 ng/µL of 
Terbinafine hydrochloride with 0.1 ng/µL of internal standard Terbinafine d7 hydrochloride in 
acetonitrile + 0.1% formic acid/ultrapure water + 0.1% formic acid (80:20). 
 
 
iv. Matrix Application 
300 mg of matrix α-CHCA was spread evenly at the bottom of the sublimation apparatus (Sigma-
Aldrich, Gillingham, UK). Polylysine glass slides containing Labskin tissues were attached to the 
flat top of the chamber. The flat top of the chamber was then attached to the bottom using the O-
ring seal and the vacuum was applied. When a stable vacuum of 2.5 x 10-2 Torr was achieved, the 
top was filled with cold water (5°C) and the temperature was set up at 180°C. The sublimation 
process was performed until the optimal amount of α-CHCA (between 0.1-0.2 mg/cm2) was 
achieved. 
 
v. Mass Spectrometry Imaging 
 
All tissues were imaged using a Waters MALDI HDMS Synapt™ G2 mass spectrometer (Waters 
Corporation, Manchester, UK) equipped with a neodynium: yttrium aluminium garnet (Nd:YAG) 
laser operated at 1 KHz. The calibration of instrument was performed by using phosphorous red. 
MALDI-MS images were acquired in positive mode, in full scan “sensitivity” mode at a range of m/z 
100-1500, (resolution 10,000 FWHM) at spatial resolution of 60 µm x 60 µm, and with laser energy 
set to 250 arbitrary units. The ion mobility function of the instrument was not enabled. 
 
vi. LC/MS/MS 
 
All LC/MS/MS experiments were performed using a Xevo G2-XS QTof (Waters Coorporation, 
Manchester, UK) with ionization mode ESI+ with analyser in sensitive mode. 
The LC conditions were made of an ACQUITY UPLC HSS T3 C18 1.7 µm, 2.1 x 100 mm (p/n 
186003539) column. The mobile phase consisted of ultrapure water (solvent A) and acetonitrile 
(solvent B) containing both 0.1% formic acid. The flow rate and the injection volume were 0.2 
mL/min and 2µL, respectively. 
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The gradient eluition was performed as follows: 0.0-2.0 min (A: 95%, B: 5%), 2.0-12.0 min (A: 5%, 
B: 95%), 12.0-30.0 min (A: 5%, B: 95%), 30.0-40.0 min (A: 95%, B: 5%), 40.0-44.0 min (A: 95%, B: 
5%).  
The experimental instrument parameters used were: capillary voltage: 3.0kV, cone voltage: 35.0V, 
source temperature: 140°C, desolvation temperature: 250°C, desolvation gas:1000L/hr and cone 
gas: 50L/hr.  
Argon was utilized as collision gas and the collision energy was set at 19eV. 
A multiple reaction monitoring (MRM) method was used to detect the product ion of Terbinafine 
(292.3  141.1 m/z) and the product ion of Terbinafine d7 (I.S.) (299  148 m/z). The retention 
time was ~ 10.6 min. 
 
vii. Skin extraction 
 
The vehicle control and treated Labskin tissues were placed for 2 min in 1X PBS pre-heated at 
60°C; then, the epidermis was separated from the dermis by using forceps, transferred to tubes 
and weighted. 
The tissue homogenisation and drug extraction were performed by a small modification of 
previously published work carried out by Sachdeva et al.21 The modification made was that after 
the second extraction, the back extraction was not performed; instead, the organic layer containing 
the extracted drug was evaporated under nitrogen and, then reconstituted in 1.8 mL of ACN/H2O 
(80:20) + 0.1% FA. The solution was filtered through a 0.22 µm filter and 0.2 mL of internal 
standard TBF d7 hydrochloride (0.1 ng/µL in ACN/H2O (80:20) + 0.1% FA) was added to the 
solutions prior to analysis.  
viii. Histological Staning 
LSE sections were stained used Mayer's haematoxylin and eosin solutions. Each slide was 
rehydrated by submerging in 100%, 95% and 70% EtOH washes for 3 min and they were left for 1 
min in deionised water before being stained in filtered Meyer's haematoxylin for 10 min. Tissues 
were washed in running tap water for 3-5 min and dehydrated using 70% and 95% EtOH solutions 
and immersed in filtered eosin 100% for 1 min. The last dehydration step was performed using 
95% and 100% EtOH solution, each for a period of 3 min. Finally, the slides were submerged in 2 
changes of xylene substitute for 5 min each and mounted using Pertex mountant.  
 
Optical images were obtained using a Cytation 5 imaging reader and analysed with Gen5 software 
(BioTek, Swindon, UK). 
 
ix. Data Analysis 
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MALDI-MSI data were processed using the HDI 1.4 (Waters Corporation, UK) software tool. 
Using this software, MSI raw data files were converted in imzML format and imported into 
MSIQuant software for quantitative investigations. 
 
For LC/MS/MS data, the chromatograms peaks for Terbinafine hydrochloride and Terbinafine d7 
hydrochloride were integrated and processed using Mass Lynx (Waters Corporation, UK) software 
tool. 
Statistical analysis was performed using the StatDirectsoftware (StatsDirect, Cheshire, UK). F test 
and T test were used to evaluate the statistical significance in terms of precision and accuracy, 
respectively, between the values obtained by MALDI-MSI and LC/MS/MS techniques. 
Three replicate measurements (n=3) were used and the level of significance was set to 5%. 
Outlier point identifications were performed using Prism software. The method selected was 
Grubbs' test for outliers (α= 0.05). 
 
 
 
Results and Discussion 
Reproducibility of droplet spot size of the Portrait 630. 
Manually spotting of calibrants onto control tissues has constituted one of the major approaches for 
generating calibration array in previous QMSI experiments.13,22-24 Although widely practiced, this 
technique is not without limitations. One of the major drawbacks of manual pipetting is the difficulty 
of depositing sub-microliter volumes of solutions. This makes it difficult to localize standards to 
small defined regions of tissue. Furthermore, manually applied spots are susceptible to variations 
in size and, hence, the amount standards in the spots are difficult to control. 
In this study we decided to measure and compare the perimeter and area of the droplet spots 
generated by the Portrait 630 in order to assess the reproducility and accuracy of this device. In 
order to perform the experiment, a solution 0.1% of gentian violet in MeOH/H2O (1:1) was used as 
a spot size marker and 9 microspots of the solution were deposited onto the epidermal layer of a 
12 µm thick blank Labskin section. In each spot the number of cycles was set to 20, with a total 
deposited volume of 3.4 nL per spot. The experiment was performed twice and, after spotting, the 
sections were imaged with a Cytation 5 imaging reader equipped with Gen5 software, while the 
perimeter and area of each spot on recorded images was measured by using ImageJ software 
(https://imagej.nih.gov/ij/). 
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The results of these experiments are shown in Supporting Information (Figure S1-A,-C). The 
presence of the dye in the solution allowed easy visualisation of the spots onto the tissue (Figure 
S1A). The average perimeter of spots for two Labskin sections was found to be 0.50 ± 0.041 mm 
and 0.53 ± 0.035 mm, respectively, while the average area was found to be 0.019 ± 0.0027 mm2 
and 0.021 ± 0.0028 mm2, respectively. The relative standard deviations of the measurements were 
as follow: 14.35% (area) and 8.21% (perimeter) from section 1; 13.50 % (area) and 6.62 % 
(perimeter) from section 2 (Figure S1B-C). 
These data demonstrate the high reproducibility in the size of the dye spots intra and inter sections 
when the Potrait spotter was used. The area and perimeter values detected from the spots in two 
sections of Labskin tissue were not statistically different. The use of Portrait 630 acoustic spotter to 
generate microspots with constant size and minimal lateral diffusion allowed better control of the 
concentration of analyte and also avoided the possibility of cross contamination that could occur for 
direct contact of the pipet with the substrate. 
 
 
Method used for quantitation 
In MALDI-MSI, the optimisation of the matrix disposition method is an essential pre-requisite for 
reproducible detection of the analyte of interest with the required sensitivity and spatial resolution. 
In previous work25 we have reported that matrix sublimation26 is an excellent methodology for the 
production of high resolution images of xenobiotic distribution in skin and 3D skin models. Figure 
1A-C shows MALDI-MSI images of the distribution of the in source generated Terbinafine fragment 
ion at m/z 141 in three sections of Labskin recorded at 60 m pixel size following treatment with 
(A) 20 l of emulsion water/olive oil (80:20) alone (vehicle control) and 20 l of Terbinafine 1% 
(w/w) in water/olive oil (80:20) with (B) 10% or (C) 50% isosorbide dimethyl ether (DMI) for 24 
hours.  It can be seen that the Terbinafine signal appears to be localized to the epidermis and that 
there is an increase in its intensity with increasing amount of DMI. 
 
In order to quantify the amount of Terbinafine in the epidermis from such images it is necessary to 
calibrate the response specifically for signals arising from the epidermis to achieve "matrix 
matched standards". Previous studies have shown that the epidermis of Labksin consists of a very 
thin differentiated layer with an average thickness of 32 µm.9,27 As discussed previously, this 
makes preparing standards by tissue spotting challenging. Therefore in this work, the use of an 
acoustic picoliter droplet ejector, used previously as a MALDI matrix deposition device,16 was used 
to spot 3.4 nL of the working standard (from 0.01 ng/µL to 1500 ng/µL) in MeOH/H2O (1:1) onto the 
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epidermis of a blank section of Labskin to create a calibration array. Internal standard Terbinafine 
d7 hydrochloride (100 ng/µl) was included into standard solutions prior to spotting and additionally 
9 spots of internal standard (100 ng/µl) were applied to the epidermal region of each treated 
sample for analysis (again using the acoustic picoliter droplet ejector). Figure 2A-D shows the MS 
image of the distribution of the m/z 148 in source generated fragment ion of Terbinafine d7 on (A) 
untreated sample along with the calibration array, (B) vehicle control skin sample treated with 20 l 
of the emulsion water/olive oil (80:20) alone and skin samples treated with Terbinafine 1% (w/w) in 
water/olive oil (80:20) with either (C) 10% or (D) 50% isosorbide dimethyl ether (DMI) for 24 hours. 
The distribution of the internal standard can be clearly seen for each spot on each section and 
hence these data are suitable for the definition of the area of spots created by the acoustic picoliter 
droplet ejector. The MSIQuant software20 allows a number of methods for the definition of regions 
of interest (ROI) and extraction of peak intensities from them for quantitative analyses. Here the 
methodology used was to exploit  signals from endogenous species to define the epidermis and 
stratum corneum of the tissue section (m/z 184 PC to define the tightly packed cells of the 
epidermis and m/z 264 to define the stratum corneum). Then using the software an average 
intensity for the signals of the Terbinafine and the Terbinafine d7 of a ROI located to solely in the 
epidermis for each spot could be extracted (Figure 3A-B). 
 
Over the past years, the use of an internal standard has been demonstrated to increase the 
quantitative capabilities of MSI analysis.28,29 The internal standard must be a molecule with 
chemical and physical caracteristics similar to the analyte under study, and, for this reason, most 
common deuterated analogues are implied. During MSI analysis the internal standard mimics the 
behavious of the analyte of interest in terms of ionization efficiency and compensates for the ion 
signal variations of the analyte tissue-dependent. This aspect causes an improvement of relative 
signal ion reproducibility and image quality due to an increase of pixel to pixel precision.14,15 
Therefore, it was decided to use a deuterated analogue of Terbinafine hydrochloride with seven 
deuterium ions on naphtalene group in order to distinguish the fragment ion of the internal standard 
to the fragment ion of the analyte in the mass spectrum, leading an increase of selectivety.  
Different approaches for applying a constant concentration of internal standard uniformly to the 
tissue have been investigated. Most commonly, an automatic spray-coating device is implied to 
deposit an internal standard either premixed with MALDI matrix13,24,30 or prior to matrix deposition31-
33 onto the tissue. Instead, we found it beneficial to apply the internal standard onto the tissue by 
microspotting in order to preserve the localization of the calibration analyte, which, instead it was 
found to migrate when the solution of Terbinafine d7 hydrochloride was sprayed onto the tissue 
(data not shown). 
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The generation of the calibration curve (n=3) was obtained by plotting either the average intensity 
of m/z 141 (Figure 3C) or the average intensity ratio of m/z 141/148 (Figure 3D) versus the 
concentration of Terbinafine expressed in ng/mm2. In agreement with previous studies, we found 
that the normalisation of the analyte signal to its deuterated analogue caused a significant 
improvement in the calibration curve linearity with a correlation coefficient (R2) from 0.9968 to 
0.9992 upon normalisation. The limits of detection (LOD) and quantitation (LOQ) were calculated; 
from these calibration data: the LOD was found to be 1.30 ng/mm2 or 0.11 mg/g tissue, whereas, 
LOQ was found to be 3.93 ng/mm2 or 0.33 mg/g tissue. 
 
 
Quantitation of the drug within the tissue. 
Using the method described above the concentration of Terbinafine in the epidermis of (A) vehicle 
control Labskin and Labskin treated with 20 l of Terbinafine 1% (w/w) in water/olive oil (80:20) 
with either (B) 10% or (C) 50% isosorbide dimethyl ether (DMI) for 24 hours was determined. In 
order to perform the experiment, a total of nine microspots with a known concentration of 
Terbinafine d7 hydrochloride (100 ng/µL) was deposited onto the epidermal layer of the vehicle 
control and treated Labskin samples. ROIs for each microspot of the TBF d7 fragment ion (m/z 
148) were drawn in corrispondence of the epidermal layer. Even in this case, the localization of the 
microspots of the Terbinafine d7 fragment ion onto the epidermis and stratum corneum was 
visualised by sumperimposing the internal standard fragment ion signal (m/z 148) with the 
phosphocoline ion signal (m/z 184) and the ceramide fragment ion signal (m/z 264). Using 
MSIQuant software, the average intensity of the Terbinafine fragment ion on each ROI was 
extracted and normalised to the average intensity of the Terbinafine d7 fragment ion (m/z 
141/148). Then, the average intensity ratio (m/z 141/148) from each spot was compared to the 
calibration curve, as shown in Figure 4A-C. 
By resolving the calibration equation, the amount of drug from each spot was obtained in ng/mm2. 
To calculate the quantitative concentration of Terbinafine hydrochloride in milligramm per gramm of 
tissue, first, the amount in gramm of tissue in 1 mm2 was detected. The volume of tissue in 1 mm2 
was calculated multiplying the area (1 mm2) by the thickness of the section (0.012 mm). Then, the 
volume (0.012 mm3) was multiplied by the density of Labskin (1 mg/mm3) and the amount of tissue 
(g) in 1 mm2 was obtained (0.000012 g). By divinding in turn the concentration of Terbinafine from 
each spot (ng/mm2) to the gramm of tissue in 1 mm2, the concentration of the drug was converted 
in milligramm per gramm of tissue. The values derived from the spots applied onto each Labskin 
section were averaged and the mean concentration of Terbinafine hydrochloride was calculated. 
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As shown in Figure 4D, in initial experiments the apparent levels of the drug were found to be 0.15 
± 0.11 mg/g tissue in vehicle control, 0.35 ± 0.047 mg/g tissue within Labskin treated with 
Terbinafine at 10% DMI, and, 0.84 ± 0.14 mg/g tissue within Labskin treated with Terbinafine at 
50% DMI. On investigation it was found that the internal standard solution used contained a small 
amount of the unlabelled drug. The problem related to deuterium-hydrogen exchange in deuterated 
compounds was previously described by Chavez et al.34 and can lead to an overestimation of the 
concentration of unlabelled analyte. To correct for this the amount of Terbinafine detected in the 
vehicle control was subtracted from the amount of Terbinafine detected in the treated tissues for 
each QMSI experiment. After this correction, at 10% DMI the concentration of TBF was found to be 
0.20 ± 0.072 mg/g of tissue (below the formal limit of quantitation), and at 50% DMI the level was 
found to be 0.69 ± 0.23 mg/g tissue. 
In order to validate the MALDI-MSI data LC/MS/MS experiments were performed using the 
methodology described by Sachdeva et al.21 LC/MS/MS is a high sensitivity technique, widely used 
in previous studies for quantification of Terbinafine hydrochloride.35,36 Although it is common 
knowledge that LC/MS/MS provides reliable quantitation, analysis using this technique can not be 
carried out directly on the intact surface skin, but analytes of interest have to be extracted out of 
the tissue, increasing the complexity of sample preparation, time of analysis and  losing spatial 
information. In addition, another drawback on using LC/MS/MS is represented by the amount of 
tissue necessary for homogenization (from 0.5 mg to 50 mg) compared to the small amount of 
tissue that can be analysed using MALDI-MSI (0.010-0.012 mg).  
LC/MS/MS experiment was repeated three times per each tissue of Labskin and the limit of 
detection (LOD) and quantitation (LOQ) were assessed at 0.42 µg/mL and 1.27 µg/mL, 
respectively. In the vehicle control sample, the levels of Terbinafine were below the limit of 
detection, whereas, at 10% DMI and 50% DMI the levels were above the LOQ and they were 
found to be 0.28 ± 0.040 mg/g tissue and 0.66 ± 0.057 mg/g tissue, respectively. 
A statistical unpaired T test was perfomed on the data from both tissues treated with Terbinafine 
with either 10% DMI or 50% DMI. The concentration of the drug resulted statistically increased in 
the tissue when the percentage of DMI increased in the formulation in both QMSI (two sided P= 
0.0256) and LC/MS/MS (two sided P= 0.0007) (Figure 4E-F). Furthermore, in order to compare the 
values obtained by QMSI and LC/MS/MS, F test and paired T test between the methods were 
performed. With the F test, the variances between the values of Terbinafine at 10% DMI and 50% 
DMI were found to be not statistically different between the methods (at 10% DMI; two sided P= 
0.478; at 50% DMI, two sided P=0.1116). When the paired T test was performed, also the means 
between the values of Terbinafine at 10% DMI and 50% DMI were found to be not statistically 
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different between the methods (at 10% DMI, two sided P=0.0726; at 50% DMI, two sided 
P=0.8361) (Figure 4G).  
These data have demonstrated the development of a QMSI method for the determination of the 
amount of an active pharmaceutical ingredient in skin. In addition the capability of the penetration 
enhancer DMI to increasing the drug penetration in the upper epidermis of living skin equivalent 
has been demonstrated. 
 
 
 
Conclusions 
 
In this article a novel approach for quantitative mass spectrometry imaging (QMSI) of Terbinafine 
hydrochloride in in the epidermal region of a full thickness living skin equivalent model, has been 
presented. The use of an acoustic spotter turned out to be ideal for applying precise and uniform 
analytical and internal standards onto a thin and well-defined epidermal layer of the Labksin tissue, 
leading to mimic cell-type based ionization response of the analyte from the treated tissue 
sections. The combination of microspotting technique and matrix sublimation allowed preserving 
the spatial distribution of the analyte and achieving better mass spectral quality and reproducibility. 
The study presented here also provided an innovative method to assess the performance of the 
penetration enhancer DMI added to the delivery vehicle. QMSI data demonstrated an increase of 
concentration of Terbinafine into the upper epidermis of Labskin in response to an increase of 
percentage of DMI in the delivery vehicle. 
QMSI data were satisfactory in showing no statistically significant differences from LC/MS/MS 
measurements of homogenates of isolated epidermal tissue, leading accuracy and precision 
between the methods to be the same. 
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Figure legends 
 
Figure 1. MALDI-MSI at 60 x 60 µm spatial resolution of the Terbinafine hydrochloride fragment 
ion ( [C11H9]
+; m/z 141) on (A) vehicle control section and two Labskin sections treated with 
Terbinafine 1% (w/w) in water/olive oil (80:20) with either (C) 10% or (D) 50% isosorbide dimethyl 
ether (DMI) for 24 hours. D) Average MALDI-MSI spectra showing the peak of the Terbinafine 
hydrochloride fragment ion at m/z 141. E) Haematoxylin & eosin stained optical image of the 
sublimated sections after MALDI-MSI (4X magnification). 
 
 
Figure 2. MALDI-MSI at 60 x 60 µm spatial resolution of the Terbinafine d7 hydrochloride source 
generated fragment ion ([C11D7H2]
+; m/z 148) microspotted directly on the epidermal layer of A) 
untreated sample along with the calibration array, (B) vehicle control section and two Labskin 
sections treated with Terbinafine 1% (w/w) in water/olive oil (80:20) with either(C) 10% or (D) 50% 
isosorbide dimethyl ether (DMI) for 24 hours. 
 
Figure 3. A) MALDI-MSI of the Terbinafine d7 source generated fragment ion in red (m/z 148) 
superimposed with choline head group in blue (m/z 184) and ceramide fragment peak in green 
(m/z 264). B) Haematoxylin & eosin stained optical image of the sublimated section after MALDI-
MSI (4X magnification). Calibration curve (n=3) generated using C) the average intensity of m/z 
141 (no normalisation) and D) the ratio average intensity of m/z 141/148. Normalisation to the 
internal standard m/z 148 improved the linearity of the calibration curve. 
 
Figure 4. MALDI-MSI of the Terbinafine d7 fragment ion in red ( m/z 148) superimposed with 
choline head group in blue (m/z 184) and ceramide fragment peak in green (m/z 264) in A) vehicle 
control section and two Labskin sections treated with Terbinafine 1% (w/w) at (B) 10% or (C) 50% 
DMI for 24 hours. The intensity of the analyte normalised to the internal standard was extracted 
from each ROI and compared to the calibration curve. D) Graph showing the initial QMSI levels of 
Terbinafine from the sections of Labskin. E) Graph showing the final levels of Terbinafine from the 
sections of Labskin after correction for the degradation of the internal standard. F) Graph showing 
the levels of Terbinafine obtained from LC/MS/MS measurements of homogenates of isolated 
epidermal tissue. G) Graph showing comparison between the results obtained from MALDI-MSI 
and LC/MS/MS, the error bars illustrates the standard deviation of three repeats for each method. 
No significant differences between the two methods were found. 
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